Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization [Seeking Alpha]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Seeking Alpha
Yoshiyoshi Hirokawa/DigitalVision via Getty ImagesIn June 2021, I authored the article,Aldeyra Therapeuticsunderlying science that promises a new approach to treating certain inflammatory diseases. Unfortunately, the past year since the publication of that article has seen a bumpy downhill ride for Aldeyra Therapeutics (NASDAQ:ALDX) shareholders and the overall meltdown in small tech biotech has exacerbated the pain. However, things are looking up again.BackgroundAs its lead indications, Aldeyra is pursuing ocular conditions of both dry eye disease (DED) and allergic conjunctivitis (AC). This article will be primarily focused on updating readers on the DED program which seems destined to become a significant value of shareholder value in the near term. I urge those unfamiliar with Aldeyra to start with my initial June 2021 article which explores their novel approach that targets Reactive Species Aldehydes or RASPs, molecules that are known to be associated with inflammation.There have
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayBusiness Wire
- Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024Business Wire
- Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 8/3/23 - Beat
ALDX
Sec Filings
- 4/25/24 - Form 8-K
- 4/25/24 - Form EFFECT
- 4/22/24 - Form ARS
- ALDX's page on the SEC website